Circulating thrombotic and haemostatic components in patients with coronary artery disease

Indian Journal of Clinical Biochemistry

Volumn 25, Issue 1, 2010, Pages 20-28

  Shalia, K K ^a   Shah, V K ^a   Mashru, M R ^a   Soneji, S L ^a   Vasvani, J B ^a   Payannavar, S S ^b   Walvalkar, A P ^a   Mokal, R A ^a   Mithbawkar, S M ^a   Kudalkar, K V ^a   Abraham, A ^a   Thakur, P K ^a  

^a Research Centre   (India)

^b Rajawadi Hospital   (India)

Author keywords

Acute myocardial infarction; Non ST elevated MI; Stable angina; Thrombotic and haemostatic components

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS;

ANGINA;

EID: 77955394198     PISSN: 09701915     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12291-010-0005-2     Document Type: Article

References (49)

1. Fuster V, Lewis A. The Conner Memorial Lecture. Mechanisms leading to acute myocardial infarction. Insights from studies of vascular biology. Circulation 1994;90:2126-46.
2. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-69.
3. Merino A, Cohen M, Badimon JJ, Fuster V, Badimon L. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis. Definition of a thrombotic shear rate threshold. J Am Coll Cardiol 1994;24:1091-7.
4. Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997;134:253-9.
5. Kamikura Y, Wada H, Yamada A, Shimura M, Hivoyama K, Shiku H, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997;55:183-7.
6. Nishiyama K, Ogawa H, Yasue H, Soejima H, Misumi K, Takazoe K et al. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J 1998;62:710-12.
7. Maly M, Vojacek J, Hrabos V, Kvasnicka J, Salaj P, Durdil V. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome. Physiol Res 2003;52:719-28.
8. Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel S, et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary arterty disease: The AtheroGene Study. J Thromb Hemost 2007;5:475-82.
9. Xiong SL, Wang Q, Zheng L, Li JL, Wen ZB, He SL. Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction. Nan Fang Yi Ke Da Xue Xue Bao 2007;27:1821-3.
10. Chen HZ, Jia HY, Song HY, Wang JY. Changes in plasma levels of tissue plasminogen activator and its inhibitor in aged myocardial infarction patients. Chin Med J (Engl) 1990;103:541-5.
11. Sakamoto T, Yasue H, Ogawa H Misumi L, Masuda T. Association of potency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol 1992;70:271-6.
12. Conri C, Seigneur M, Constans J, Mercier P, Baste JC, Dufourcq P, et al. Evidence of elevated soluble plasma thrombomodulin in atherosclerosis. J Mal Vasc 1993;18:112-8.
13. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Wienehall L, Huhtasaari F, et al. High PAI-1 and tPA levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-7.
14. Mannucci PM, Bernardinelli L, Foco L, Galli M, Ribichini F, Tubaro M, et al. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. J Thromb Hemost 2005;3:280-6.
15. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 2001;21:611-7. (Pubitemid 32323396)
16. Ganti Ak, Potti A, Yegnanarayan R. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction. Pathophysiol Haemost Thromb 2002;32:80-4.
17. Mackman N, Morrissey JH, Fowler B, Edgington TS. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochem 1989;28:1755-62.
18. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-43.
19. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000;101:841-3.
20. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon TJ, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-5.
21. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004;110:452-9.
22. Schecter AD, Spirn B, Rossikhina M, Giesen PL, Bogdanov V, et al. Release of active tissue factor by human arterial smooth muscle cells. Circ Res 2000;87:126-32.
23. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003;9:458-62.
24. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005;96:1233-9.
25. Lindhal AK. Tissue factor pathway inhibitor: From unknown coagulation inhibitor to major anti thrombogenic principle. Cardiovascular Res 1997;33:286-91.
26. Sandset PM. Tissue factor pathway inhibitor-an update (TFPI). Haemostasis 1996;26(Suppl 4):154-65.
27. Caplice NM, Mueske CS, Kleppe LS, Simari RD. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998;98:1051-57.
28. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999;188:180-8. (Pubitemid 29253938)
29. Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C. Expression, localization and activity of TFPI in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000;20:1362-73.
30. Guha M, O'Connel MA, Pawlinski R, Hollis A, McGovern P, Yan SF, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001;98:1429-39.
31. Ott I, Andrassy M, Zieglgansberger D, Geith S, Schomig A, Neumann FJ. Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1. Blood 2001;97:3721-6.
32. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002;22(4):539-48.
33. Mousa SA. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. Int Angiol 2006:10-13.
34. Saito Y, Wada H, Yamamuro M, Inoue A, Shimura M, Hiyoyama K, et al. Changes in plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am J Hematol 1999;61:238-42.
35. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998;79:495-9.
36. Al-Nozha MM, Abdel-Gader AG, Arafah MR, Al-Maatouq MA, Al-Shahid MS, Al-Harthi SS, et al. Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes. Saudi Med J 2005;26:937-42.
37. Novo G, Caplice N, Tantillo R, Bonura F, Simari R, Novo S. TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications. Int Angiol 2005;24; 366-71.
38. Wang HB, Kang WQ, Song DL, Wang X, Ren GR, Teng JL, et al. Relationship between tissue type plasminogen activator and coronary vulnerable plaque in patients with acute coronary syndrome: virtual histological study. Chin Med J (Engl) 2008;121:540-3.
39. Hoffmeister HM, Jur M, Ruf-Lehmann M, Helber U, Heller W, Seipel L. Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol 1998;31:547-51.
40. Yan J, Huang Z, Liu R, Li L, Han C, Yang J. A study on the reserve capacity of endothelial tissue plasminogen activator in patients with acute coronary syndrome. Zhonghua Nei Ke Za Zhi 1999;38:817-20.
41. Hoffmeister HM, Heller W, Seipel L. Blood coagulation and fibrinolysis in arteriosclerosis Z Kardiol 1999;88:315-23.
42. Shindo J, Ishibashi T, Kijima M, Nakazato K, Nagata K, Yokoyama K, et al. Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes. Coron Artery Dis 2001;12:573-9.
43. Chen F, Eriksson P, Hansson GK, Herzfeld I, Klein M, Hansson LO, et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med 2005;15:57-65.
44. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Wienehall L, Huhtasaari F, et al. High PAI-1 and tPA levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-7.
45. Hamstein A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
46. Chen Y, Wang J, Yao Y, Yuan W, Kong M, Lin Y, et al. CRP regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. FEBS Lett 2009;583:2811-8.
47. Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. Creactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol 2008:698-704.
48. Cirillo P, Golino P, Calabro P, Cali G, Ragni M, De Rosa S, et al. Creactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 2005;68:47-55.
49. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005:2216-21.